cmAngio® vs Zio ECG Utilization Software (ZEUS) System
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography data for early cardiovascular risk assessment in women. This AI software is ideal for identifying Breast Arterial Calcifications (BAC) on routine mammograms (FFDM and DBT) to provide insights into a patient's cardiovascular health without requiring additional radiation or procedures. It helps integrate cardiovascular risk insights into routine breast cancer screening workflows.
View cmAngio® →Choose Zio ECG Utilization Software (ZEUS) System if…
Choose the Zio ECG Utilization Software (ZEUS) System if you need to diagnose and manage patients with suspected or known cardiac arrhythmias through continuous, long-term ECG monitoring. This AI-powered, cloud-based platform is best suited for analyzing extended ECG data from wearable Zio monitors to accurately detect and classify arrhythmias, providing comprehensive end-of-wear reports for physician review and aiding in treatment decisions.
View Zio ECG Utilization Software (ZEUS) System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Zio ECG Utilization Software (ZEUS) System |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based. |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A (cmAngiou00ae) emphasizes quick installation, taking less than an hour, and broad compatibility with any DICOM-compliant viewer, allowing seamless integration into existing radiology workflows. It provides clear visualization of Breast Arterial Calcification (BAC) locations on a scorecard, minimizing disruption to a radiologist's current process.
Clinical Value
Zio ECG Utilization Software (ZEUS) SystemTool B (ZEUS) offers significant clinical value through its FDA-cleared AI algorithms for continuous ECG data analysis, aiding in the diagnosis and management of cardiac arrhythmias. Clinical studies demonstrate its high diagnostic yield, lower retesting rates compared to other monitoring services, and a 99% physician agreement rate on its end-of-wear reports.
Pricing & Value
Zio ECG Utilization Software (ZEUS) SystemBoth tools have opaque pricing, making a direct cost comparison difficult. However, Tool B (ZEUS) offers patient payment programs, including financial assistance and installment plans, which enhances accessibility for patients. Furthermore, it provides no-cost setup for EHR integration with Epic via the Aura network, indicating a commitment to reducing implementation barriers for healthcare systems.
Enterprise Readiness
Zio ECG Utilization Software (ZEUS) SystemTool B (ZEUS) demonstrates superior enterprise readiness with explicit mentions of HL7-based EHR integration, including a seamless, no-cost integration with Epic via the Aura network. It also highlights a robust cloud-based architecture on AWS EC2, featuring high scalability, durability, and redundant systems, which are critical for enterprise deployments.
Innovation
cmAngio®Tool A (cmAngiou00ae) showcases a more novel application of AI by repurposing existing mammography data to detect Breast Arterial Calcifications (BAC) for cardiovascular risk assessment. This transforms a routine breast cancer screening into a 'two-for-one exam' without additional radiation, leveraging an established imaging modality for a new and impactful diagnostic insight.
Support & Docs
Zio ECG Utilization Software (ZEUS) SystemTool B (ZEUS) provides readily available 'Instructions for Use' and 'Patient Support and FAQs' online, offering clear guidance for both clinicians and patients. It also lists customer care contact details for some regions, indicating a more transparent and accessible support structure compared to Tool A, which offers less specific information on support and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Zio ECG Utilization Software (ZEUS) System |
|---|---|---|
| Name | cmAngiou00ae | Zio ECG Utilization Software (ZEUS) System |
| Company | CureMetrix | iRhythm Technologies |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered, cloud-based platform that analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias. |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | AI algorithm for arrhythmia detection and classification |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Continuous ECG data analysis (up to 14 days) |
| Key Feature 3 | Provides visualization of BAC location on a scorecard | Cloud-based data analytics (AWS EC2 platform) |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Zio ECG Utilization Software (ZEUS) System.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or Zio ECG Utilization Software (ZEUS) System
Backers
Who funded each tool's parent company.